Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oxford BioMedicaOXBDF 72 Net Cash per Share is $-1.52 as of Dec. 2025. GuruFocus rates OXBDF with a GF Score™ of 72/100 and a GF Value™ of $7.22 (Fairly Valued). The stock has 5 warning signs investors should review. Among 795 Biotechnology companies, Oxford BioMedica ranks worse than 125786.04% on this metric.
The historical rank and industry rank for Oxford BioMedica's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Oxford BioMedica was 17.83. The lowest was 17.83. And the median was 17.83.
OXBDF's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.3 * Ranked among companies with meaningful Price-to-Net-Cash only.
Oxford BioMedica (OTCPK:OXBDF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Oxford BioMedica Net Cash per Share Related Terms
Oxford BioMedica Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OXBDF vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Oxford BioMedica's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Oxford BioMedica's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (OXBDF) has a Net Cash per Share of $-1.52 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Oxford BioMedica and its competitors. Over the past decade, Oxford BioMedica's Net Cash per Share has ranged from 17.83 to 17.83. According to the industry distribution chart, Oxford BioMedica ranks #999999 out of 795 companies in the Biotechnology industry.
Is Oxford BioMedica's Net Cash per Share too high?
Oxford BioMedica's current Net Cash per Share is $-1.52. Over the past 10 years, this metric has ranged from a low of 17.83 to a high of 17.83. Based on the distribution chart, Oxford BioMedica ranks #999999 out of 795 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oxford BioMedica has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #999999 out of 795 companies for Net Cash per Share. This places Oxford BioMedica in the lower half of its industry. The industry median Net Cash per Share is 5.30. Historically, Oxford BioMedica's own Net Cash per Share has ranged from 17.83 to 17.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.30, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Oxford BioMedica and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current Net Cash per Share is $-1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Fairly Valued. The stock's GF Value™ is $7.22, compared to a current price of $7.34 — trading 1.7% above its estimated fair value. The current Net Cash per Share is $-1.52. Oxford BioMedica's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Net Cash per Share is $-1.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (OXBDF) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of $7.34 is trading 1.7% above its estimated GF Value™ of $7.22.
GuruFocus considers Oxford BioMedica to be Fairly Valued.
Key valuation signals for OXBDF:
Net Cash per Share: $-1.52
GF Value™: $7.22 vs. price of $7.34 (1.7% above fair value)
No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
72GF Score
Get the complete analysis for OXBDF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBDF has been successfully added to your 
